Hypoxic Ischaemic Encephalopathy clinical trials

Explore recruiting hypoxic ischaemic encephalopathy clinical trials.

Recruiting hypoxic ischaemic encephalopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypoxic Ischaemic Encephalopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.

Ireland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.

Bulgaria

Human Pharmacology (Phase I)- Other EU CTIS Study details

Oxytocin versus Prostaglandins for labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening: a multicenter non inferiority randomized trial (OPIC)

France

Phase III and phase IV (Integrated) EU CTIS Study details

Hypoxic Ischaemic Encephalopathy trials by city

Hypoxic Ischaemic Encephalopathy in Toronto Hypoxic Ischaemic Encephalopathy in Vancouver Hypoxic Ischaemic Encephalopathy in Montreal Hypoxic Ischaemic Encephalopathy in Calgary Hypoxic Ischaemic Encephalopathy in Edmonton Hypoxic Ischaemic Encephalopathy in Ottawa Hypoxic Ischaemic Encephalopathy in Winnipeg Hypoxic Ischaemic Encephalopathy in Quebec City Hypoxic Ischaemic Encephalopathy in Hamilton Hypoxic Ischaemic Encephalopathy in Kitchener Hypoxic Ischaemic Encephalopathy in London Hypoxic Ischaemic Encephalopathy in Halifax Hypoxic Ischaemic Encephalopathy in New York Hypoxic Ischaemic Encephalopathy in Los Angeles Hypoxic Ischaemic Encephalopathy in Chicago Hypoxic Ischaemic Encephalopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease